2019 成人噬血细胞性淋巴组织细胞增多症的管理建议

2019-04-16 组织细胞学会 Blood. 2019 Apr 16.

噬血细胞性淋巴组织细胞增多症(HLH)是由异常活化的巨噬细胞和细胞毒性T细胞诱导的一种严重过度炎症综合征。本文主要针对成人HLH的治疗提供共识建议。

中文标题:

2019 成人噬血细胞性淋巴组织细胞增多症的管理建议

英文标题:

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.

发布机构:

组织细胞学会

发布日期:

2019-04-16

简要介绍:

噬血细胞性淋巴组织细胞增多症(HLH)是由异常活化的巨噬细胞和细胞毒性T细胞诱导的一种严重过度炎症综合征。本文主要针对成人HLH的治疗提供共识建议。 

拓展指南:淋巴相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 成人噬血细胞性淋巴组织细胞增多症的管理建议)] GetToolGuiderByIdResponse(projectId=1, id=265d21c001e3a009, title=2019 成人噬血细胞性淋巴组织细胞增多症的管理建议, enTitle=Recommendations for the management of hemophagocytic lymphohistiocytosis in adults., guiderFrom=Blood. 2019 Apr 16., authorId=null, author=, summary=噬血细胞性淋巴组织细胞增多症(HLH)是由异常活化的巨噬细胞和细胞毒性T细胞诱导的一种严重过度炎症综合征。本文主要针对成人HLH的治疗提供共识建议。 , cover=, journalId=null, articlesId=null, associationId=1702, associationName=组织细胞学会, associationIntro=, copyright=0, guiderPublishedTime=Tue Apr 16 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>噬血细胞性淋巴组织细胞增多症(HLH)是由异常活化的巨噬细胞和细胞毒性T细胞诱导的一种严重过度炎症综合征。本文主要针对成人HLH的治疗提供共识建议。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>淋巴</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=1fb921c001e3307f" title="西罗莫司治疗淋巴管肌瘤病专家共识(2018)" target=_blank>西罗莫司治疗淋巴管肌瘤病专家共识(2018)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=906611c001e30a62" title="NCCN临床实践指南:霍奇金淋巴瘤(2019.V1)" target=_blank>NCCN临床实践指南:霍奇金淋巴瘤(2019.V1)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=3c1e31c001e299e8" title="NCCN临床实践指南:急性淋巴细胞白血病(2019.V1)" target=_blank>NCCN临床实践指南:急性淋巴细胞白血病(2019.V1)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=f36f51c001e2a2f4" title="甲状腺及相关颈部淋巴结超声若干临床常见问题专家共识(2018版)" target=_blank>甲状腺及相关颈部淋巴结超声若干临床常见问题专家共识(2018版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=aa6531c001e230d3" title="2018 外科共识指南:口腔癌患者前哨淋巴结活检" target=_blank>2018 外科共识指南:口腔癌患者前哨淋巴结活检</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E6%B7%8B%E5%B7%B4" target=_blank>有关淋巴更多指南</a></ul>, tagList=[TagDto(tagId=89483, tagName=成人噬血细胞性淋巴组织细胞增多症)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6123, appHits=645, showAppHits=0, pcHits=4515, showPcHits=1719, likes=58, shares=456, comments=7, approvalStatus=1, publishedTime=Mon May 06 22:50:35 CST 2019, publishedTimeString=2019-04-16, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon May 06 22:50:35 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 18:49:16 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 成人噬血细胞性淋巴组织细胞增多症的管理建议)])
2019 成人噬血细胞性淋巴组织细胞增多症的管理建议
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1075273, encodeId=c74e10e527378, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Tue Nov 30 06:17:53 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001901, encodeId=01ef10019011a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTILNb9HsuNn3RWfMhwWGjRrl48MFoyWWcHTNtEao4baNUYOIV5qyd3BZbibGRxNmmpYicCyG52IIXnQ/132, createdBy=b3162571325, createdName=hainao, createdTime=Fri Jul 23 08:17:56 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001861, encodeId=6ea610018615b, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 22 23:21:49 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807607, encodeId=b9d480e6070f, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200824/adf7aecfa5784daea5f08c970b83d994/0c12e9fb19ae40d08386eb25dc4582a2.jpg, createdBy=61c72495945, createdName=1248aed9m52暂无昵称, createdTime=Wed Aug 12 08:08:15 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807594, encodeId=b12e80e594fd, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0acb2570971, createdName=12582d2fm84暂无昵称, createdTime=Wed Aug 12 06:12:46 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2021-11-30 yike168

    很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1075273, encodeId=c74e10e527378, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Tue Nov 30 06:17:53 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001901, encodeId=01ef10019011a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTILNb9HsuNn3RWfMhwWGjRrl48MFoyWWcHTNtEao4baNUYOIV5qyd3BZbibGRxNmmpYicCyG52IIXnQ/132, createdBy=b3162571325, createdName=hainao, createdTime=Fri Jul 23 08:17:56 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001861, encodeId=6ea610018615b, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 22 23:21:49 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807607, encodeId=b9d480e6070f, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200824/adf7aecfa5784daea5f08c970b83d994/0c12e9fb19ae40d08386eb25dc4582a2.jpg, createdBy=61c72495945, createdName=1248aed9m52暂无昵称, createdTime=Wed Aug 12 08:08:15 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807594, encodeId=b12e80e594fd, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0acb2570971, createdName=12582d2fm84暂无昵称, createdTime=Wed Aug 12 06:12:46 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2021-07-23 hainao

    谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1075273, encodeId=c74e10e527378, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Tue Nov 30 06:17:53 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001901, encodeId=01ef10019011a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTILNb9HsuNn3RWfMhwWGjRrl48MFoyWWcHTNtEao4baNUYOIV5qyd3BZbibGRxNmmpYicCyG52IIXnQ/132, createdBy=b3162571325, createdName=hainao, createdTime=Fri Jul 23 08:17:56 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001861, encodeId=6ea610018615b, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 22 23:21:49 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807607, encodeId=b9d480e6070f, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200824/adf7aecfa5784daea5f08c970b83d994/0c12e9fb19ae40d08386eb25dc4582a2.jpg, createdBy=61c72495945, createdName=1248aed9m52暂无昵称, createdTime=Wed Aug 12 08:08:15 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807594, encodeId=b12e80e594fd, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0acb2570971, createdName=12582d2fm84暂无昵称, createdTime=Wed Aug 12 06:12:46 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2021-07-22 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1075273, encodeId=c74e10e527378, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Tue Nov 30 06:17:53 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001901, encodeId=01ef10019011a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTILNb9HsuNn3RWfMhwWGjRrl48MFoyWWcHTNtEao4baNUYOIV5qyd3BZbibGRxNmmpYicCyG52IIXnQ/132, createdBy=b3162571325, createdName=hainao, createdTime=Fri Jul 23 08:17:56 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001861, encodeId=6ea610018615b, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 22 23:21:49 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807607, encodeId=b9d480e6070f, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200824/adf7aecfa5784daea5f08c970b83d994/0c12e9fb19ae40d08386eb25dc4582a2.jpg, createdBy=61c72495945, createdName=1248aed9m52暂无昵称, createdTime=Wed Aug 12 08:08:15 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807594, encodeId=b12e80e594fd, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0acb2570971, createdName=12582d2fm84暂无昵称, createdTime=Wed Aug 12 06:12:46 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 1248aed9m52暂无昵称

    不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1075273, encodeId=c74e10e527378, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78301384513, createdName=yike168, createdTime=Tue Nov 30 06:17:53 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001901, encodeId=01ef10019011a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTILNb9HsuNn3RWfMhwWGjRrl48MFoyWWcHTNtEao4baNUYOIV5qyd3BZbibGRxNmmpYicCyG52IIXnQ/132, createdBy=b3162571325, createdName=hainao, createdTime=Fri Jul 23 08:17:56 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001861, encodeId=6ea610018615b, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 22 23:21:49 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807607, encodeId=b9d480e6070f, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200824/adf7aecfa5784daea5f08c970b83d994/0c12e9fb19ae40d08386eb25dc4582a2.jpg, createdBy=61c72495945, createdName=1248aed9m52暂无昵称, createdTime=Wed Aug 12 08:08:15 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807594, encodeId=b12e80e594fd, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0acb2570971, createdName=12582d2fm84暂无昵称, createdTime=Wed Aug 12 06:12:46 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 12582d2fm84暂无昵称

    不错

    0